Phase I and Pharmacokinetic Study of a Low-Clearance, Unilamellar Liposomal Formulation of Lurtotecan, a Topoisomerase 1 Inhibitor, in Patients with Advanced Leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Camptothecin
  • Leukemia, Myeloid
  • Topoisomerase I Inhibitors

abstract

  • Liposomal encapsulation of lurtotecan altered its metabolism significantly. There was no evident correlation between exposure, as measured by plasma pharmacokinetics of lurtotecan, and clinical response or toxicities. OSI-211 merits further study in hematologic malignancies.

publication date

  • April 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.20132

PubMed ID

  • 15042679

Additional Document Info

start page

  • 1449

end page

  • 58

volume

  • 100

number

  • 7